Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 23 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.28 Insider Own26.90% Shs Outstand44.45M Perf Week-7.16%
Market Cap2.12B Forward P/E- EPS next Y-2.34 Insider Trans-11.34% Shs Float39.26M Perf Month-3.61%
Income-95.99M PEG- EPS next Q-0.55 Inst Own61.48% Short Float16.12% Perf Quarter131.92%
Sales0.00M P/S- EPS this Y-0.16% Inst Trans1.76% Short Ratio4.44 Perf Half Y301.63%
Book/sh2.29 P/B17.28 EPS next Y-3.97% ROA-62.54% Short Interest6.33M Perf Year505.21%
Cash/sh2.99 P/C13.21 EPS next 5Y- ROE-107.50% 52W Range6.07 - 50.78 Perf YTD156.96%
Dividend Est.- P/FCF- EPS past 5Y10.22% ROI-62.76% 52W High-22.17% Beta1.12
Dividend TTM- Quick Ratio7.42 Sales past 5Y0.00% Gross Margin- 52W Low551.07% ATR (14)3.36
Dividend Ex-Date- Current Ratio7.42 EPS Y/Y TTM31.36% Oper. Margin0.00% RSI (14)45.66 Volatility7.54% 8.06%
Employees51 Debt/Eq0.53 Sales Y/Y TTM- Profit Margin- Recom1.36 Target Price55.80
Option/ShortYes / Yes LT Debt/Eq0.50 EPS Q/Q50.54% Payout- Rel Volume0.85 Prev Close39.13
Sales Surprise- EPS Surprise-8.12% Sales Q/Q- EarningsMar 20 BMO Avg Volume1.43M Price39.52
SMA20-4.55% SMA50-9.19% SMA20069.39% Trades Volume1,216,326 Change1.00%
Date Action Analyst Rating Change Price Target Change
Jan-25-24Initiated Oppenheimer Outperform $26
Jan-08-24Initiated Cantor Fitzgerald Overweight
Dec-18-23Initiated Raymond James Outperform $29
Nov-10-23Upgrade Jefferies Hold → Buy $18 → $26
Aug-16-23Initiated Guggenheim Buy $27
Jan-04-23Downgrade Wedbush Outperform → Neutral $33 → $8
Jan-04-23Downgrade Jefferies Buy → Hold $32 → $6
Jul-12-22Initiated JP Morgan Overweight $35
May-02-22Initiated H.C. Wainwright Buy $35
Apr-19-22Initiated Wedbush Outperform $32
Apr-23-24 05:09PM
Apr-13-24 05:29AM
Apr-12-24 07:01PM
Apr-11-24 04:29PM
Apr-05-24 06:30PM
08:00AM Loading…
Apr-02-24 08:00AM
Mar-20-24 12:52PM
Feb-28-24 04:20PM
Feb-02-24 12:40PM
Feb-01-24 04:05PM
Jan-29-24 11:50PM
Jan-25-24 06:30AM
06:44PM Loading…
Jan-12-24 06:44PM
Jan-08-24 08:01AM
Dec-27-23 08:00AM
Dec-15-23 10:15AM
Nov-14-23 05:05PM
Nov-09-23 09:29AM
Nov-04-23 10:00AM
Oct-30-23 08:00AM
Oct-18-23 09:35AM
Oct-17-23 09:35AM
Oct-16-23 09:35AM
Oct-13-23 10:22AM
04:02PM Loading…
Sep-26-23 04:02PM
Aug-31-23 08:00AM
Aug-16-23 10:00AM
Aug-15-23 04:03PM
Aug-10-23 08:00AM
Aug-04-23 06:30PM
Jul-24-23 09:01AM
Jul-07-23 06:35PM
Jun-27-23 08:05AM
Jun-20-23 07:04PM
Jun-17-23 10:10AM
Jun-15-23 04:44PM
Jun-12-23 12:05PM
Jun-11-23 01:08PM
Jun-08-23 08:00AM
Jun-07-23 08:00AM
May-11-23 08:36AM
May-04-23 08:00AM
Mar-28-23 07:30AM
Feb-27-23 04:05PM
Feb-14-23 07:48AM
Feb-09-23 06:51AM
Feb-06-23 04:05PM
Feb-01-23 09:52PM
Jan-30-23 07:35AM
Jan-25-23 08:00AM
Jan-22-23 07:39AM
Jan-06-23 05:02AM
Jan-04-23 04:07PM
Jan-03-23 04:01PM
Dec-20-22 04:05PM
Nov-25-22 07:38AM
Nov-22-22 07:30AM
Nov-17-22 07:30AM
Nov-09-22 07:30AM
Nov-05-22 04:50PM
Oct-17-22 07:30AM
Sep-15-22 09:55AM
Sep-07-22 07:30AM
Aug-29-22 09:55AM
Aug-12-22 09:55AM
Aug-10-22 07:30AM
Aug-04-22 07:30AM
Jul-06-22 07:30AM
Jun-18-22 08:20AM
Jun-04-22 02:30PM
Jun-02-22 07:30AM
May-20-22 04:05PM
May-16-22 07:30AM
May-05-22 04:05PM
May-03-22 04:33PM
May-02-22 07:06PM
Apr-12-22 07:30AM
Mar-24-22 06:30AM
Mar-21-22 07:30AM
Mar-17-22 07:30AM
Mar-01-22 07:30AM
Feb-22-22 05:29AM
Feb-14-22 04:01PM
Feb-10-22 08:46AM
Feb-07-22 05:24PM
Jan-18-22 07:30AM
Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCRApr 10 '24Sale40.005,714228,56053,171Apr 12 04:02 PM
Grant SeanCHIEF FINANCIAL OFFICERApr 03 '24Option Exercise14.8799,8281,484,442166,165Apr 05 09:32 PM
Grant SeanCHIEF FINANCIAL OFFICERApr 03 '24Sale39.6199,8283,954,51666,337Apr 05 09:32 PM
Grant SeanCHIEF FINANCIAL OFFICERApr 03 '24Sale39.4218,649735,2050Apr 05 09:32 PM
Katabi MahaDirectorMar 25 '24Sale40.50340,00013,770,0002,793,987Mar 25 09:46 PM
Katabi MahaDirectorMar 22 '24Sale40.51413,45016,748,8603,133,987Mar 25 09:46 PM
Katabi MahaDirectorMar 21 '24Sale44.2081,0093,580,7233,547,437Mar 25 09:46 PM
Katabi MahaDirectorJan 30 '24Buy31.00161,2904,999,9903,628,446Feb 01 05:58 PM
COMMODORE CAPITAL LP10% OwnerJan 10 '24Sale18.001,050,00018,900,0004,400,000Jan 12 09:55 PM
Fordyce MarshallPresident and CEODec 29 '23Option Exercise2.8713,51638,854256,877Jan 03 04:15 PM
Fordyce MarshallPresident and CEOAug 21 '23Sale16.665,21086,779243,361Aug 23 05:56 PM
Curley JoanneChief Development OfficerAug 21 '23Sale16.661,49024,81726,962Aug 23 05:57 PM
Lin CeliaChief Medical OfficerAug 21 '23Sale16.651,49024,81611,010Aug 23 05:59 PM
Young Joseph RSVP, Finance, Chief Acct OffcrJul 05 '23Option Exercise3.9410,00039,39632,679Jul 06 04:05 PM
Grant SeanChief Financial OfficerJun 23 '23Buy16.605,00083,0005,992Jun 23 04:05 PM
COMMODORE CAPITAL LP10% OwnerJun 20 '23Buy15.17448,2176,799,0045,450,000Jun 22 04:10 PM